Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1 - 7 |
| Number of pages | 7 |
| Journal | Journal of Cardiac Failure |
| Volume | 13 |
| Issue number | 1 |
| Publication status | Published - 2007 |
Cite this
}
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. / Krum, Henry; Ashton, Emma Louise; Reid, Christopher Michael; Kalff, Victor; Rogers, Jim; Amarena, John; Singh, Bhuwan; Tonkin, Andrew Maxwell.
In: Journal of Cardiac Failure, Vol. 13, No. 1, 2007, p. 1 - 7.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure
AU - Krum, Henry
AU - Ashton, Emma Louise
AU - Reid, Christopher Michael
AU - Kalff, Victor
AU - Rogers, Jim
AU - Amarena, John
AU - Singh, Bhuwan
AU - Tonkin, Andrew Maxwell
PY - 2007
Y1 - 2007
N2 - Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]
AB - Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]
UR - http://www.elsevier.com/locate/cardfail
M3 - Article
VL - 13
SP - 1
EP - 7
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
SN - 1071-9164
IS - 1
ER -